Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Conditions
Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Triple-Negative Breast Carcinoma · Metastatic Triple-Negative Breast Carcinoma · Unresectable Triple-Negative Breast Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Boston Medical Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Jose J. Acevedo Mejia)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Ana C. Garrido-Castro)NYU Langone Hospital - Long Island, Mineola, New York, United States
Contact: Principal Investigator (Nancy Chan)Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Contact: Principal Investigator (Nancy Chan)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Kai C. Johnson)Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States
Contact: Principal Investigator (Vandana G. Abramson)
Study leads
Ana C Garrido-Castro
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO